Reversal of Anticoagulant Effects in Patients with Intracerebral Hemorrhage

Stroke (HP Adams, Section Editor)

DOI: 10.1007/s11910-014-0504-2

Cite this article as:
Yates, S. & Sarode, R. Curr Neurol Neurosci Rep (2015) 15: 504. doi:10.1007/s11910-014-0504-2
Part of the following topical collections:
  1. Topical Collection on Stroke


Anticoagulant therapies are increasingly being used for the treatment and prevention of thromboembolic diseases. A growing incidence of anticoagulant-associated intracranial hemorrhage (AICH) has accompanied the rise in their use. Although the rate of intracerebral hemorrhage (ICH) in patients receiving anticoagulation therapies such as heparin and target-specific oral anticoagulants (TSOAs) is significantly lower than that of vitamin K antagonists (VKAs), the mortality rate remains high. TSOAs have only recently become available for use in clinical practice, and presently, there is a paucity of both clinical data and evidence-based guidelines to assist in the management of TSOA-associated intracerebral hemorrhage. In this article, we review current literature and provide physicians with diagnostic and therapeutic considerations for the management of AICH.


Anticoagulants Apixaban Dabigatran Intracerebral hemorrhage Target-specific oral anticoagulants Prothrombin complex concentrate Rivaroxaban Vitamin K Warfarin 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Transfusion Medicine and Hemostasis, Department of PathologyUT Southwestern Medical CenterDallasUSA

Personalised recommendations